Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
Incyte Has Decided Not To Proceed With The Planned Phase 3 MAESTRA-3 Study Evaluating INCB123667; Company Does Not Expect This Determination To Affect Its Financial Guidance Or Its Previously Disclosed Long-term Outlook
Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030
Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
Leerink Partners Maintains Outperform on Incyte, Lowers Price Target to $150
$1000 Invested In Incyte 20 Years Ago Would Be Worth This Much Today
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
Incyte to Present at Upcoming Investor Conferences
Incyte To Present New Data On Its 30 Abstracts At American Society Of Hematology Annual Meeting
Bernstein Maintains Market Perform on Incyte, Raises Price Target to $108
INCY Q3 deep dive: product diversification accelerates as R&D spending weighs on margins
Wells Fargo Maintains Equal-Weight on Incyte, Lowers Price Target to $127
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $117
Barclays Maintains Overweight on Incyte, Raises Price Target to $143
Evercore ISI Group Maintains In-Line on Incyte, Raises Price Target to $127
Oppenheimer Upgrades Incyte to Outperform, Raises Price Target to $144
Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap
Incyte Corporation Q3 2026 Earnings Call Summary
Incyte (INCY) Q3 2026 Earnings Call Transcript
What Incyte (INCY) Said on Its Q3 Earnings Call
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.